内分泌指南

订阅

MedSci主页 / 所有栏目 / 内分泌指南

COVID-19 和代谢疾病：机制和临床管理

2021-10-04 欧洲代谢专家组 Lancet Diabetes Endocrinol

代谢疾病Covid-19

多达 50% 的死于 COVID-19 的人患有代谢和血管疾病。值得注意的是，COVID-19 与代谢和内分泌系统之间存在许多直接联系。

中文标题：

COVID-19 和代谢疾病：机制和临床管理

发布机构：

欧洲代谢专家组

发布日期：

2021-10-04

简要介绍：

多达 50% 的死于 COVID-19 的人患有代谢和血管疾病。值得注意的是，COVID-19 与代谢和内分泌系统之间存在许多直接联系。因此，不仅代谢功能障碍（如肥胖、高血压、非酒精性脂肪肝和糖尿病）患者发生严重 COVID-19 的风险增加，而且感染 SARS-CoV-2 也可能导致新的-糖尿病发作或原有代谢紊乱加重。在这篇综述中，我们更新了代谢和内分泌疾病如何使患者易患严重 COVID-19 的机制。此外，我们更新了 COVID-19 和大流行后患者的实用建议和管理与 COVID-19 和糖尿病患者的新治疗方案。

相关资料下载：
[AttachmentFileName(sort=1, fileName=COVID-19 和代谢疾病：机制和临床管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=b0b261c00226197e, title=COVID-19 和代谢疾病：机制和临床管理, enTitle=, guiderFrom=Lancet Diabetes Endocrinol, authorId=0, author=, summary=多达 50% 的死于 COVID-19 的人患有代谢和血管疾病。值得注意的是，COVID-19 与代谢和内分泌系统之间存在许多直接联系。, cover=https://img.medsci.cn/20211112/1636706664313_5579292.jpg, journalId=0, articlesId=null, associationId=2121, associationName=欧洲代谢专家组, associationIntro=欧洲代谢专家组, copyright=0, guiderPublishedTime=Mon Oct 04 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #505050;">多达 50% 的死于 COVID-19 的人患有代谢和血管疾病。</span><span style="color: #505050;">值得注意的是，COVID-19 与代谢和内分泌系统之间存在许多直接联系。</span><span style="color: #505050;">因此，不仅代谢功能障碍（如肥胖、高血压、非酒精性脂肪肝和糖尿病）患者发生严重 COVID-19 的风险增加，而且感染 SARS-CoV-2 也可能导致新的-糖尿病发作或原有代谢紊乱加重。</span><span style="color: #505050;">在这篇综述中，我们更新了代谢和内分泌疾病如何使患者易患严重 COVID-19 的机制。</span><span style="color: #505050;">此外，我们更新了 COVID-19 和大流行后患者的实用建议和管理与</span><span style="color: #505050;"> COVID-19 和糖尿病患者的新治疗方案。</span></p>, tagList=[TagDto(tagId=12674, tagName=代谢疾病), TagDto(tagId=99632, tagName=Covid-19)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌, tenant=100), CategoryDto(categoryId=9, categoryName=传染科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=99632, guiderKeyword=Covid-19, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=41990, appHits=78, showAppHits=0, pcHits=330, showPcHits=41911, likes=1, shares=5, comments=4, approvalStatus=1, publishedTime=Tue Nov 16 23:57:56 CST 2021, publishedTimeString=2021-10-04, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=dajiong, createdTime=Sat Nov 13 13:27:29 CST 2021, updatedBy=4754896, updatedName=小小医者, updatedTime=Wed Jan 03 18:47:24 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=COVID-19 和代谢疾病：机制和临床管理.pdf)])
COVID-19 和代谢疾病：机制和临床管理.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1219954, encodeId=80c31219954d1, content=<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon May 16 10:44:17 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186696, encodeId=f49e118669638, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=318c2889934, createdName=mispj, createdTime=Fri Jan 21 08:40:36 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073726, encodeId=f0bb10e372634, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0e5721051, createdName=ms6000000706879309, createdTime=Thu Nov 25 07:44:09 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073353, encodeId=8c6c10e3353e5, content=学习下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=db263045094, createdName=lzs51382, createdTime=Wed Nov 24 00:30:10 CST 2021, time=2021-11-24, status=1, ipAttribution=)]
    2022-05-16 赛华佗

    #代谢#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1219954, encodeId=80c31219954d1, content=<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon May 16 10:44:17 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186696, encodeId=f49e118669638, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=318c2889934, createdName=mispj, createdTime=Fri Jan 21 08:40:36 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073726, encodeId=f0bb10e372634, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0e5721051, createdName=ms6000000706879309, createdTime=Thu Nov 25 07:44:09 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073353, encodeId=8c6c10e3353e5, content=学习下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=db263045094, createdName=lzs51382, createdTime=Wed Nov 24 00:30:10 CST 2021, time=2021-11-24, status=1, ipAttribution=)]
    2022-01-21 mispj

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1219954, encodeId=80c31219954d1, content=<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon May 16 10:44:17 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186696, encodeId=f49e118669638, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=318c2889934, createdName=mispj, createdTime=Fri Jan 21 08:40:36 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073726, encodeId=f0bb10e372634, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0e5721051, createdName=ms6000000706879309, createdTime=Thu Nov 25 07:44:09 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073353, encodeId=8c6c10e3353e5, content=学习下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=db263045094, createdName=lzs51382, createdTime=Wed Nov 24 00:30:10 CST 2021, time=2021-11-24, status=1, ipAttribution=)]
    2021-11-25 ms6000000706879309

    好好学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1219954, encodeId=80c31219954d1, content=<a href='/topic/show?id=91eb2540054' target=_blank style='color:#2F92EE;'>#代谢#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25400, encryptionId=91eb2540054, topicName=代谢)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=赛华佗, createdTime=Mon May 16 10:44:17 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186696, encodeId=f49e118669638, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=318c2889934, createdName=mispj, createdTime=Fri Jan 21 08:40:36 CST 2022, time=2022-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073726, encodeId=f0bb10e372634, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0e5721051, createdName=ms6000000706879309, createdTime=Thu Nov 25 07:44:09 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073353, encodeId=8c6c10e3353e5, content=学习下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=db263045094, createdName=lzs51382, createdTime=Wed Nov 24 00:30:10 CST 2021, time=2021-11-24, status=1, ipAttribution=)]
    2021-11-24 lzs51382

    学习下

    0

相关指南

2019 SIE共识声明：代谢疾病管理中极低热量生酮饮食

意大利内分泌学会(SIE,Italian Society of Endocrinology) · 2019-05-20

拓展阅读

2019冠状病毒病(COVID-19)疫情防控期间妇科急诊患者临床诊疗防护原则和措施的建议

暂未更新 · 2020-02-18

COVID-19感染患者的气管切开术共识：西班牙

西班牙重症监护医学与冠心病小组学会(SEMICYUC,Spanish Society of Intensive Care Medicine and Coronary Units) · 2020-06-01

OVID-19大流行期间妇科恶性肿瘤的放射治疗：国际专家共识建议

暂未更新 · 2020-06-23

在COVID-19大流行期间接受治疗性放疗的肺癌患者管理共识

暂未更新 · 2020-09-01

肺癌和COVID-19大流行：巴西胸部肿瘤小组的建议

巴西胸部肿瘤组织（Brazilian Thoracic Oncology Group） · 2020-09-01

COVID-19患者的化学预防，诊断，治疗和出院管理：循证临床实践指南（更新版本）

中国医院协会(CHA,Chinese Hospital Association) ·